Anti-PD-1 Therapy for Patients with Advanced Cholangiocarcinoma: Ready for Prime Time?
作者信息
Brar Gagandeep, Shroff Rachna T
机构信息
Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Division of Hematology and Oncology, University of Arizona Cancer Center, Tucson, AZ, USA.
出版信息
J Immunother Precis Oncol. 2025 May 12;8(2):181-183. doi: 10.36401/JIPO-25-X3. eCollection 2025 May.
Abstract
摘要
相似文献
1
Anti-PD-1 Therapy for Patients with Advanced Cholangiocarcinoma: Ready for Prime Time?抗程序性死亡蛋白1（PD-1）疗法用于晚期胆管癌患者：已准备好进入黄金时代了吗？
J Immunother Precis Oncol. 2025 May 12;8(2):181-183. doi: 10.36401/JIPO-25-X3. eCollection 2025 May.
2
Real-world outcomes of chemotherapy plus immune checkpoint inhibitors versus chemotherapy alone in advanced, unresectable, and recurrent intrahepatic cholangiocarcinoma.晚期不可切除和复发性肝内胆管癌中化疗联合免疫检查点抑制剂与单纯化疗的真实世界结局。
Front Immunol. 2024 May 23;15:1390887. doi: 10.3389/fimmu.2024.1390887. eCollection 2024.
3
Successful Treatment of Advanced Intrahepatic Cholangiocarcinoma With a High Tumor Mutational Burden and PD-L1 Expression by PD-1 Blockade Combined With Tyrosine Kinase Inhibitors: A Case Report.PD-1 阻断联合酪氨酸激酶抑制剂治疗高肿瘤突变负荷和 PD-L1 表达的晚期肝内胆管细胞癌 1 例报告。
Front Immunol. 2021 Sep 17;12:744571. doi: 10.3389/fimmu.2021.744571. eCollection 2021.
4
AJCC 8th edition staging system for pathologically versus clinically staged intrahepatic cholangiocarcinoma (iCCA): ready for prime time?美国癌症联合委员会（AJCC）第8版肝内胆管癌（iCCA）病理分期与临床分期系统：准备好进入黄金时代了吗？
Chin Clin Oncol. 2019 Oct;8(S1):S19. doi: 10.21037/cco.2019.04.04. Epub 2019 May 6.
5
Lenvatinib Combined With a PD-1 Inhibitor as Effective Therapy for Advanced Intrahepatic Cholangiocarcinoma.乐伐替尼联合PD-1抑制剂作为晚期肝内胆管癌的有效治疗方法。
Front Pharmacol. 2022 Jun 1;13:894407. doi: 10.3389/fphar.2022.894407. eCollection 2022.
6
Integration of radiotherapy with anti-PD-1 antibody for the treatment of intrahepatic or hilar cholangiocarcinoma: reflection from four cases.放疗联合抗 PD-1 抗体治疗肝内或肝门部胆管癌：来自 4 个病例的启示。
Cancer Biol Ther. 2021 Mar 4;22(3):175-183. doi: 10.1080/15384047.2020.1834792. Epub 2021 Mar 15.
7
Liver Transplantation for Intrahepatic Cholangiocarcinoma: Ready for Prime Time?肝移植治疗肝内胆管细胞癌：是否已经成熟？
Hepatology. 2022 Feb;75(2):455-472. doi: 10.1002/hep.32258. Epub 2022 Jan 6.
8
Hepatic arterial infusion chemotherapy plus lenvatinib with or without programmed cell death protein-1 inhibitors for advanced cholangiocarcinoma.肝动脉灌注化疗联合仑伐替尼加或不加程序性死亡蛋白-1 抑制剂治疗晚期胆管癌。
Front Immunol. 2023 Aug 30;14:1235724. doi: 10.3389/fimmu.2023.1235724. eCollection 2023.
9
Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study.PD-1 抑制剂联合仑伐替尼和 Gemox 化疗作为晚期肝内胆管细胞癌一线治疗的疗效、安全性和预后因素：一项多中心真实世界研究。
Cancer Immunol Immunother. 2023 Sep;72(9):2949-2960. doi: 10.1007/s00262-023-03466-8. Epub 2023 May 29.
10
Immune-related adverse events correlate with the efficacy of PD-1 inhibitors combination therapy in advanced cholangiocarcinoma patients: A retrospective cohort study.免疫相关不良反应与晚期胆管癌患者 PD-1 抑制剂联合治疗的疗效相关：一项回顾性队列研究。
Front Immunol. 2023 Mar 24;14:1141148. doi: 10.3389/fimmu.2023.1141148. eCollection 2023.
本文引用的文献
1
Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study.托法替布在胆管癌患者中的安全性和有效性：一项开放标签的1期研究。
J Immunother Precis Oncol. 2025 Jan 15;8(1):71-81. doi: 10.36401/JIPO-24-8. eCollection 2025 Feb.
2
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers.SWOG S1815：一项针对新诊断的晚期胆管癌患者，比较吉西他滨、顺铂和白蛋白结合型紫杉醇与吉西他滨和顺铂疗效的III期随机试验。
J Clin Oncol. 2025 Feb 10;43(5):536-544. doi: 10.1200/JCO-24-01383. Epub 2024 Dec 13.
3
Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial.纳洛昔单抗脂质体伊立替康联合氟尿嘧啶和亚叶酸与氟尿嘧啶和亚叶酸在吉西他滨治疗后胆管癌和胆囊癌患者中的应用（AIO NALIRICC）：一项多中心、开放标签、随机、2 期临床试验。
Lancet Gastroenterol Hepatol. 2024 Aug;9(8):734-744. doi: 10.1016/S2468-1253(24)00119-5. Epub 2024 Jun 10.
4
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.度伐利尤单抗联合吉西他滨和顺铂治疗晚期胆道癌。
NEJM Evid. 2022 Aug;1(8):EVIDoa2200015. doi: 10.1056/EVIDoa2200015. Epub 2022 Jun 1.
5
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.帕博利珠单抗联合吉西他滨和顺铂与单纯吉西他滨和顺铂治疗晚期胆道癌患者的比较（KEYNOTE-966）：一项随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2023 Jun 3;401(10391):1853-1865. doi: 10.1016/S0140-6736(23)00727-4. Epub 2023 Apr 16.
6
Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study.特泊替尼联合仑伐替尼和 GEMOX 作为一线治疗晚期肝内胆管癌的方案具有广阔前景：一项单中心、单臂、Ⅱ期研究。
Signal Transduct Target Ther. 2023 Mar 17;8(1):106. doi: 10.1038/s41392-023-01317-7.
7
Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study.脂质体伊立替康联合氟尿嘧啶和亚叶酸治疗吉西他滨和顺铂治疗后进展的转移性胆道癌（NIFTY）：一项多中心、开放标签、随机、2b 期研究。
Lancet Oncol. 2021 Nov;22(11):1560-1572. doi: 10.1016/S1470-2045(21)00486-1. Epub 2021 Oct 14.
8
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.晚期胆管癌二线FOLFOX化疗与积极症状控制的对比研究（ABC-06）：一项3期、开放标签、随机对照试验
Lancet Oncol. 2021 May;22(5):690-701. doi: 10.1016/S1470-2045(21)00027-9. Epub 2021 Mar 30.
9
A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.纳武利尤单抗治疗晚期难治性胆道癌患者的 2 期多中心研究。
JAMA Oncol. 2020 Jun 1;6(6):888-894. doi: 10.1001/jamaoncol.2020.0930.
10
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.顺铂联合吉西他滨与吉西他滨治疗胆管癌。
N Engl J Med. 2010 Apr 8;362(14):1273-81. doi: 10.1056/NEJMoa0908721.
Zotero 插件